|
US20030157064A1
(en)
*
|
2001-11-09 |
2003-08-21 |
Pascal Neuville |
Chimeric promoters for controlling expression in muscle cells
|
|
US20080044393A1
(en)
*
|
2004-07-16 |
2008-02-21 |
White Robert L |
Retinal dystrophin transgene and methods of use thereof
|
|
US8557969B2
(en)
|
2004-12-01 |
2013-10-15 |
The Regents Of The University Of Michigan |
Compositions and methods for regulating cardiac performance
|
|
WO2008054713A2
(en)
*
|
2006-10-30 |
2008-05-08 |
Thomas Jefferson University |
Tissue specific gene therapy treatment
|
|
US20120322861A1
(en)
*
|
2007-02-23 |
2012-12-20 |
Barry John Byrne |
Compositions and Methods for Treating Diseases
|
|
CA2834729A1
(en)
|
2011-04-06 |
2012-10-11 |
Universite Pierre Et Marie Curie (Paris 6) |
A skeletal muscle-specific enhancer
|
|
KR20150020250A
(ko)
|
2012-06-19 |
2015-02-25 |
유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 |
당뇨병을 치료하기 위한 조성물 및 방법
|
|
US9845465B2
(en)
|
2012-08-15 |
2017-12-19 |
University Of Virginia Patent Foundation |
Compositions and methods for treating peripheral arterial disease
|
|
WO2014100714A1
(en)
|
2012-12-20 |
2014-06-26 |
Sarepta Therapeutics, Inc. |
Improved exon skipping compositions for treating muscular dystrophy
|
|
KR20250047401A
(ko)
|
2013-03-14 |
2025-04-03 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근육 이영양증의 치료를 위한 엑손 스키핑 조성물
|
|
KR20240094032A
(ko)
|
2013-03-14 |
2024-06-24 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근육 이영양증의 치료를 위한 엑손 스키핑 조성물
|
|
WO2015035364A1
(en)
*
|
2013-09-09 |
2015-03-12 |
University Of Washington Through Its Center For Commercialization |
Proteins for targeting neuronal nitric oxide synthase to muscle sarcolemma and related methods of use
|
|
SG11201605906UA
(en)
|
2014-01-21 |
2016-08-30 |
Univ Bruxelles |
Muscle-specific nucleic acid regulatory elements and methods and use thereof
|
|
KR102458219B1
(ko)
|
2015-03-05 |
2022-10-24 |
피터 운드 트라우들 앵겔호른-스티프텅 주르 푀르데룽 데르 레벤스위센샤프텐 |
세포 표면 상에 펩타이드를 제시하기 위한 시스템
|
|
GB201508025D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Fabry disease gene therapy
|
|
CN104894651B
(zh)
*
|
2015-06-29 |
2017-04-12 |
天津诺禾医学检验所有限公司 |
微量起始dna的高通量测序文库构建方法及其所构建的高通量测序文库
|
|
HK1257519A1
(zh)
*
|
2015-09-17 |
2019-10-25 |
Research Institute At Nationwide Children's Hospital |
用於 galgt2 基因治療的方法和物質
|
|
CA3020754C
(en)
|
2016-04-14 |
2023-07-25 |
Benitec Biopharma Limited |
Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof
|
|
EP3471544B1
(en)
|
2016-06-21 |
2021-12-22 |
The Curators Of The University Of Missouri |
Modified dystrophin proteins
|
|
CA3071978A1
(en)
|
2017-08-03 |
2019-02-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
US11434502B2
(en)
|
2017-10-16 |
2022-09-06 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (ALS)
|
|
EP4454654A3
(en)
|
2017-10-16 |
2025-02-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
WO2019153009A1
(en)
|
2018-02-05 |
2019-08-08 |
Audentes Therapeutics, Inc. |
Transcription regulatory elements and uses thereof
|
|
JP7467356B2
(ja)
*
|
2018-02-07 |
2024-04-15 |
ジェネトン |
ハイブリッド調節要素
|
|
CA3097192A1
(en)
|
2018-04-27 |
2019-10-31 |
Voyager Therapeutics, Inc. |
Methods for measuring the potency of aadc viral vectors
|
|
EP3793616A1
(en)
|
2018-05-15 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
US12319929B2
(en)
|
2018-05-15 |
2025-06-03 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of Parkinson's disease
|
|
US12060567B2
(en)
|
2018-06-13 |
2024-08-13 |
Voyager Therapeutics, Inc. |
Engineered untranslated regions (UTR) for AAV production
|
|
US20210254103A1
(en)
|
2018-07-02 |
2021-08-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
|
|
US20210348242A1
(en)
|
2018-10-04 |
2021-11-11 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
WO2020072844A1
(en)
|
2018-10-05 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
US20210395777A1
(en)
|
2018-10-15 |
2021-12-23 |
Voyager Therapeutics, Inc. |
EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM
|
|
MX2021005720A
(es)
|
2018-11-16 |
2021-07-21 |
Astellas Pharma Inc |
Metodo para tratar la distrofia muscular mediante el direccionamiento del gen de utrofina.
|
|
JP2022522995A
(ja)
|
2019-01-18 |
2022-04-21 |
ボイジャー セラピューティクス インコーポレイテッド |
Ａａｖ粒子を生成するための方法及びシステム
|
|
AU2020229886B2
(en)
|
2019-02-28 |
2025-09-18 |
Benitec IP Holdings Inc. |
Compositions and methods for treating oculopharyngeal muscular dystrophy (OPMD)
|
|
KR20210148273A
(ko)
*
|
2019-04-08 |
2021-12-07 |
제네똥 |
근육 발현을 위한 하이브리드 프로모터
|
|
WO2020227515A1
(en)
|
2019-05-07 |
2020-11-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
BR112021023899A2
(pt)
|
2019-05-28 |
2022-01-18 |
Astellas Pharma Inc |
Método para o tratamento da distrofia muscular por direcionamento ao gene da dmpk
|
|
KR20220045013A
(ko)
|
2019-08-16 |
2022-04-12 |
가부시키가이샤 모달리스 |
Lama1 유전자를 표적으로 하는 근이영양증의 치료 방법
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
EP4126910A1
(en)
|
2020-04-01 |
2023-02-08 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
BR112022020753A2
(pt)
|
2020-04-15 |
2022-12-20 |
Voyager Therapeutics Inc |
Compostos de ligação a tau
|
|
PE20230767A1
(es)
|
2020-05-13 |
2023-05-09 |
Voyager Therapeutics Inc |
Redireccion del tropismo de las capsides de aav
|
|
WO2021230385A1
(en)
|
2020-05-15 |
2021-11-18 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting utrophin gene
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
CA3192120A1
(en)
*
|
2020-09-11 |
2022-03-17 |
James A. Williams |
Muscle-specific hybrid promoter
|
|
US20220098615A1
(en)
|
2020-09-30 |
2022-03-31 |
NGGT, Inc. |
Dual functional expression vectors and methods of use thereof
|
|
EP4228610A1
(en)
|
2020-10-13 |
2023-08-23 |
Kriya Therapeutics, Inc. |
Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
|
|
WO2022114243A1
(en)
|
2020-11-25 |
2022-06-02 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting dmpk gene
|
|
EP4284936A1
(en)
|
2021-01-26 |
2023-12-06 |
Kriya Therapeutics, Inc. |
Vector constructs for delivery of nucleic acids encoding therapeutic anti-tnf antibodies and methods of using the same
|
|
EP4036238A1
(en)
*
|
2021-01-27 |
2022-08-03 |
The University Court of the University of Edinburgh |
Functional nucleic acid molecule and method
|
|
WO2022174113A1
(en)
|
2021-02-12 |
2022-08-18 |
Merand Pharmaceuticals, Inc. |
Agents, compositions, and methods for the treatment of hypoxia and ischemia-related disorders
|
|
WO2022187679A1
(en)
|
2021-03-04 |
2022-09-09 |
Kriya Therapeutics, Inc. |
Viral vector constructs incorporating dna for inhibiting toll like receptors and methods of using the same
|
|
CA3226119A1
(en)
*
|
2021-08-04 |
2023-02-09 |
Giuseppe RONZITTI |
Hybrid promoters for gene expression in muscles and in the cns
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
CN118317944A
(zh)
|
2021-09-14 |
2024-07-09 |
雷纳嘉德医疗管理公司 |
非环状脂质及其使用方法
|
|
CA3232386A1
(en)
|
2021-09-14 |
2023-03-23 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and methods of use thereof
|
|
US20250223376A1
(en)
|
2021-09-20 |
2025-07-10 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
MX2024008509A
(es)
|
2022-01-09 |
2024-07-19 |
Kriya Therapeutics Inc |
Construcciones de vectores para la distribucion de acidos nucleicos que codifican anticuerpos terapeuticos anti-igf-1r y metodos para usarlos.
|
|
US20250243510A1
(en)
*
|
2022-03-16 |
2025-07-31 |
Rutgers, The State University Of New Jersey |
Controlled muscle-specific gene delivery
|
|
WO2023196931A1
(en)
|
2022-04-07 |
2023-10-12 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
|
EP4522757A2
(en)
|
2022-05-13 |
2025-03-19 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
US20250243263A1
(en)
|
2022-06-22 |
2025-07-31 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
US20260009003A1
(en)
*
|
2022-07-11 |
2026-01-08 |
Vita Therapeutics, Inc. |
Manufacturing of therapeutic satellite cells for treating muscular dystrophy
|
|
AU2023342086A1
(en)
|
2022-09-15 |
2025-03-13 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
WO2025014832A1
(en)
|
2023-07-07 |
2025-01-16 |
Kriya Therapeutics, Inc. |
Periocular delivery of aav vectors for treating ophthalmic pathologies
|